血漿治療市場規模、佔有率和成長分析（按類型、來源、應用、最終用戶和地區）- 產業預測 2025-2032

2023 年全球血漿治療市場規模價值為 3.1 億美元，預計將從 2024 年的 3.5433 億美元成長到 2032 年的 10.3223 億美元，預計在預測期內（2025-2032 年）到 2032 年將達到 1 億美元)預計將以14.3%的複合年成長率成長。

由於男性脫髮症和運動相關傷害的增加，血漿治療市場預計將成長。由於血漿具有高濃度的抗體，其治療用途可提供免疫轉移，並且在整形外科、皮膚科和牙科方面特別有益。富血小板血漿 (PRP) 在各個治療領域的應用日益廣泛，也成為主要的成長催化劑。然而，缺乏報銷框架、與血漿療法相關的各種費用以及糖尿病和腎衰竭患者的療效有限等挑戰可能會阻礙市場擴張。此外，關節炎病例的急劇增加可能會減緩成長。總體而言，不斷成長的患者需求和新的治療應用的融合為該領域的相關人員提供了重要的未來機會。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究分析

血漿治療市場規模（按類型）

• 市場概況
• 純 PRP
• 富含白血球的 PRP
• 純血小板中富含纖維蛋白
• 富含纖維蛋白的白血球

血漿治療市場規模（依供應來源）

• 市場概況
• 家
• 同一物種

血漿治療市場規模（按應用）

• 市場概況
• 整形外科
  • 關節炎
  • 慢性肌腱炎
  • 骨修復和再生
• 皮膚科
  • 男性脫髮症
  • 整形外科
• 心肌損傷
• 牙科
• 神經損傷
• 其他

血漿治療市場規模（按最終用戶分類）

• 市場概況
• 醫院和診所
• 研究組織

血漿治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• CSL Behring（Australia）
• Grifols SA（Spain）
• Kedrion SpA（Italy）
• Octapharma AG（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• Zimmer Biomet（US）
• Baxter International Inc.（US）
• China Biologic Products Holdings, Inc.（China）
• GC Pharma（South Korea）
• Green Cross Corp.（South Korea）
• Japan Blood Products Organization（Japan）
• LFB SA（France）
• Shanghai RAAS Blood Products Co., Ltd.（China）
• China National Biotec Group Co., Ltd.（CNBG）（China）
• Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.（China）
• Jiangxi Boya Bio-Pharmaceutical Co., Ltd.（China）
• Bio Products Laboratory Ltd.（BPL）（UK）
• BioLife Plasma Services（US）
• Canadian Plasma Resources（Canada）

結論和建議

Global Plasma Therapy Market size was valued at USD 310.0 million in 2023 and is poised to grow from USD 354.33 million in 2024 to USD 1032.23 million by 2032, growing at a CAGR of 14.3% during the forecast period (2025-2032).

The market for plasma therapy is poised for growth, driven by the increasing incidence of androgenic alopecia and sports-related injuries. With plasma's high antibody concentration, its therapeutic application offers immunity transfer, particularly beneficial in orthopaedics, dermatology, and dentistry. The rising adoption of platelet-rich plasma (PRP) across various therapeutic areas is also a significant growth catalyst. However, challenges such as the lack of reimbursement frameworks, varied costs associated with plasma therapy, and limited efficacy in diabetic and kidney-compromised patients may hinder market expansion. Additionally, the surge in arthritis cases could moderate growth. Overall, the convergence of increasing patient demand and emerging treatment applications presents substantial future opportunities for stakeholders in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Plasma Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Therapy Market Segmental Analysis

Global Plasma Therapy Market is segmented by Type, Source, Application, End User and region. Based on Type, the market is segmented into Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin. Based on Source, the market is segmented into Autologous and Allogenic. Based on Application, the market is segmented into Orthopedic, Dermatology, Cardiac Muscle Injury, Dental, Nerve Injury and Others. Based on End User, the market is segmented into Hospitals & Clinics and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Plasma Therapy Market

The Global Plasma Therapy market is experiencing significant growth due to several driving factors. A notable increase in the use of platelet-rich plasma (PRP) is attributed to a surge in sports injuries, along with a rising demand for cosmetic procedures, as more individuals engage in athletic activities. Additionally, the expanded application of PRP in research is further propelling the sector forward. As awareness of the benefits of plasma therapy continues to grow, fueled by its effectiveness in healing and rejuvenation, the market is well-positioned for continued expansion, attracting both medical professionals and patients alike.

Restraints in the Global Plasma Therapy Market

The Global Plasma Therapy market faces significant restraints primarily due to the high costs associated with the treatment. The expenses involved in extracting plasma from blood and the subsequent storage requirements pose a challenge to market growth. In both developing and underdeveloped regions, these costs have greatly limited the accessibility and utilization of plasma therapy. As a result, the average individual often finds the treatment financially out of reach, which serves as a major barrier to market expansion. Consequently, the high financial burden associated with plasma therapy remains one of the primary factors hindering its wider adoption and development.

Market Trends of the Global Plasma Therapy Market

The global plasma therapy market is poised for significant growth driven by an increasing prevalence of androgenic alopecia and orthopedic disorders. As healthcare advancements expand treatment options, consumers are now empowered to select therapies aligned with their financial capabilities, thus enhancing market accessibility. Nevertheless, challenges persist, notably the limited application of platelet-rich plasma (PRP) in patients with diabetes and kidney issues, which may hinder market expansion. Additionally, the rise of innovative healthcare technologies is improving treatment efficacy, particularly for rare diseases, fostering increased interest in plasma therapies. Overall, these trends indicate a dynamic future landscape for the plasma therapy market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Plasma Therapy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Pure PRP
• Leukocyte-Rich PRP
• Pure Platelet-Rich Fibrin
• Leukocyte-Rich Fibrin

Global Plasma Therapy Market Size by Source & CAGR (2025-2032)

• Market Overview
• Autologous
• Allogenic

Global Plasma Therapy Market Size by Application & CAGR (2025-2032)

• Market Overview
• Orthopedic
  • Arthritis
  • Chronic Tendinitis
  • Bone Repair & Regeneration
• Dermatology
  • Androgenic Alopecia
  • Plastic Surgery
• Cardiac Muscle Injury
• Dental
• Nerve Injury
• Others

Global Plasma Therapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Research Institutes

Global Plasma Therapy Market Size & CAGR (2025-2032)

• North America (Type, Source, Application, End User)
  • US
  • Canada
• Europe (Type, Source, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Source, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Source, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Source, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zimmer Biomet (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Pharma (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corp. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Japan Blood Products Organization (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China National Biotec Group Co., Ltd. (CNBG) (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (BPL) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioLife Plasma Services (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canadian Plasma Resources (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations